SOMERSET, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, today announced it has received a favorable review by Forbes. Forbes highlighted CareCloud’s ability to cater to both small and large practices while offering advanced analtics to facilitate data-driven decision making.
In an article published in Forbes Advisor, the renowned business publication highlights CareCloud's user-friendly, comprehensive features and its ability to streamline operations for medical practices of all sizes. The review applauds CareCloud's user-friendly interface, advanced billing capabilities, and robust reporting tools, which enable healthcare providers to optimize their practice efficiency and financial performance. The review notes CareCloud's intuitive scheduling module, which facilitates appointment management and reduces patient wait times. Additionally, the software's mobile app enables healthcare providers to access patient records, schedule appointments, and submit claims on-the-go, enhancing the flexibility and convenience for medical professionals.
CareCloud’s solutions reviewed by Forbes include:
Forbes also highlights the effectiveness of tools like CareCloud Breeze and CareCloud Live. Breeze is a mobile patient portal that simplifies patient registration, intake, and check-ins, and offers a convenient payment platform. With customizable electronic intake forms and preregistration, CareCloud Breeze optimizes efficiency by saving time for office staff and reducing in-office wait times. Live is a telehealth portal enabling secure HIPAA-compliant video calls between practiioners and patients. Compatible with multimple platforms, CareCloud Live ensures easy access and facilitates secure two-way interactions for remote healthcare services.
"CareCloud’s aim is to consistently offer cost-effective and innovative solutions that cater to medical practices of all sizes,” said Carinda Cox, vice president of sales at CareCloud. "We are unwavering in our commitment to continuously improve these solutions, ensuring they offer the utmost support for practices to deliver enhanced care. We are honored to receive such commendation from Forbes, a globally trusted source of business information. Moving forward, we will continue to deliver solutions and services that exceed expectations and set new standards."
To learn more about CareCloud’s comprehensive suite of technology-enabled services and solutions, visit carecloud.com/solutions. If you would like to inquire further about how CareCloud can specifically help your practice, email Cox at This email address is being protected from spambots. You need JavaScript enabled to view it..
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
Company Contact:
Bill Korn
Chief Strategy Officer
CareCloud
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.02 |
Daily Change: | -0.03 -1.56 |
Daily Volume: | 6,938 |
Market Cap: | US$32.810M |
May 06, 2025 April 07, 2025 April 02, 2025 March 26, 2025 March 13, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load